For this reason, here, we examined for potential enduring FLX-induced changes in protein expression of ERK1/2, its downstream effector ribosomal S6 kinase (RSK), as well as mammalian target of rapamycin (mTOR) within this brain region—given the role these molecules play in modulating depression-related and antidepressant-like outcomes in adult organisms without juvenile antidepressant history [16–18]. This evidence concerns the gene MTOR and major depressive disorder.